Simultaneously targeting NT signaling in PNI and cancer cells is still a suject of debate as the design of specific inhibitors of Trk, whose aberrant oncogenic expression is observed in both peripheral nerve fibers and cancer cells, is complex. Here, NTRK1 is linked to cancer.